fbpx Skip to main content

Public Policy Newsletter Article

Hope on the Horizon, But Challenges Remain

  • 2021-04-22T15:00:00.000+0000
  • Author: Jimmy Jackson

It’s hard to believe that Q1 2021 is now behind us and we continue to progress toward some sense of “normalcy.” Along those lines, some big news this month was Governor Gavin Newsom’s announcement that, provided vaccine supplies remain adequate and COVID hospitalization rates remain stable, the state will “fully reopen” on June 15. Some modifications (indoor masking, other adaptations) are expected to be ordered. The Biocom California policy team will continue to notify our members of these updated guideline as soon as they are known.

Regional emergency orders on re-opening continue to vary greatly. Many counties follow what the state will allow. Other counties such as Los Angeles and San Francisco, are taking a more restrictive approach to their re-opening. See the variations among key life science counties here and stay tuned for future changes as our team monitors the situation on a daily and sometimes hourly basis.

In Washington, ideas for price control legislation, including foreign reference pricing, continue to percolate among some federal lawmakers. Biocom California is actively working with national and regional partners (such as CLSA) to coordinate education campaigns with Members of Congress. Learn more about these efforts.

In other nation’s capital news, Biocom California wrote in support of the delayed CMS MCIT (Medicare Coverage of Innovative Technologies) rule. The implementation of this rule would provide immediate Medicare reimbursement for devices authorized through FDA's breakthrough device program and is a top priority for Biocom California and our medical device members.

Finally, in legislation that impacts our small pre-commercial and multinational members alike, Biocom California is a proud co-sponsor of Assembly Bill 593, legislation that would reinstate the ability of life science companies to fully utilize research and development credits and net operating loss carryforwards. Read about the bill’s progress here.